Furthermore, our findings suggest a novel dietary combination of DNA methyltransferase and histone deacetylase inhibitors contribute to ER re-expression in ER-negative breast cancer for the effective treatment of hormonal refractory breast cancers (HRBCs) with available SERMs. The gene discussed is ESR1; the disease is breast cancer.